Carboplatin-based systemic therapy superior to cetuximab for cisplatin-ineligible HNSCC
Carboplatin-based systemic therapy appeared associated with longer survival than cetuximab among patients with head and neck squamous cell carcinoma ineligible for cisplatin, according to study results.
An analysis of a cohort of U.S. veterans treated with carboplatin or cetuximab (Erbitux, Eli Lilly) showed longer OS in the carboplatin group (HR = 0.85; 95% CI, 0.78-0.93).
The findings suggest carboplatin may be the preferred radiosensitizer for cisplatin-ineligible patients undergoing chemoradiation, particularly for patients with oropharynx cancers, researchers concluded.
Healio spoke with investigator Lova L. Sun, MD, MSCE, medical oncologist at University of Pennsylvania, about the findings and their potential implications.
Collapse
Read more about